Literature DB >> 2224769

Expression of pancreatic secretory trypsin inhibitor gene in human colorectal tumor.

N Tomita1, S Doi, M Higashiyama, H Morimoto, M Murotani, Y Kawasaki, T Monden, T Shimano, A Horii, H Yokouchi.   

Abstract

Expression of pancreatic secretory trypsin inhibitor (PSTI) gene was examined by Northern blotting analyses in 31 human colorectal tumors that included two benign adenomas and 26 adenocarcinomas. Among the total of 28 cases which proved to be adequate for mRNA analyses, all but one showed the expression of PSTI at various levels. In contrast, PSTI expression was not detected in two malignant lymphomas of the rectum. The level of PSTI expression was not correlated with the patient's age, sex, tumor location or size, stage of differentiation, lymph node metastasis, or progression stage. Some colorectal adenocarcinomas were also shown to express genes that can hybridize with human trypsinogen cDNA probe. It looks as though in these tumors, a protease(s) and its inhibitor are produced simultaneously as part of a cellular self-defense mechanism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2224769     DOI: 10.1002/1097-0142(19901115)66:10<2144::aid-cncr2820661017>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis.

Authors:  Jason Lamontagne; Mark Pinkerton; Timothy M Block; Xuanyong Lu
Journal:  J Virol       Date:  2009-10-28       Impact factor: 5.103

2.  Role of the inflammatory protein serine protease inhibitor Kazal in preventing cytolytic granule granzyme A-mediated apoptosis.

Authors:  Felix Lu; Jason Lamontagne; Angela Sun; Mark Pinkerton; Timothy Block; Xuanyong Lu
Journal:  Immunology       Date:  2011-12       Impact factor: 7.397

3.  Overexpression of pancreatic secretory trypsin inhibitor in pancreatic cancer. Evaluation of its biological function as a growth factor.

Authors:  Y Ohmachi; A Murata; N Matsuura; T Yasuda; K Uda; T Mori
Journal:  Int J Pancreatol       Date:  1994-02

4.  Quantification of pancreatic secretory trypsin inhibitor in colonic carcinoma and normal adjacent colonic mucosa.

Authors:  H Bohe; M Bohe; P Jönsson; C Lindström; K Ohlsson
Journal:  J Clin Pathol       Date:  1992-12       Impact factor: 3.411

5.  Role of Intrapancreatic SPINK1/Spink3 Expression in the Development of Pancreatitis.

Authors:  Masaki Ohmuraya; Aki Sugano; Masahiko Hirota; Yutaka Takaoka; Ken-Ichi Yamamura
Journal:  Front Physiol       Date:  2012-05-07       Impact factor: 4.566

6.  TATI (tumour-associated trypsin inhibitor) as a marker of ovarian cancer.

Authors:  M Medl; E Ogris; C Peters-Engl; S Leodolter
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

Review 7.  New intracellular and molecular aspects in pathophysiology of colorectal cancer.

Authors:  Payman Ziapour; Ramin Ataee; Mohammad Shadifar; Cathy Vaillancourt; Ali Ahmadi; Majid Jafari-Sabet; Amin Ataee
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2011
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.